Gene Expression Test Can Lead to More Effective Treatment Decisions In Patients With Invasive Lobular Carcinoma (ILC) Breast Cancer

Michaela Tsai, MD, breast cancer researcher at Virginia Piper Cancer Institute at Abbott Northwestern Hospital

[Oncology Nurse Advisor, January 01, 0001] Most patients with invasive lobular carcinoma (ILC) breast cancer could be treated with hormones alone and not with chemotherapy, according to a study published in Clinical Breast Cancer (2015; doi:10.1016/j.clbc.2015.08.001). This study analyzed the use of the Oncotype DX gene expression test to predict recurrence of invasive lobular carcinoma.

Researchers reviewed all consecutive cases of ILC breast cancer diagnosed at the Allina Health Laboratory (affiliated with the Virginia Piper Cancer Institute at Abbott Northwestern Hospital in Minneapolis, Minnesota) in the past 8 years.